Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.29
-0.3800-4.95%
Post-market: 7.350.0600+0.82%19:46 EDT
Volume:4.51M
Turnover:33.74M
Market Cap:1.60B
PE:-5.16
High:7.71
Open:7.63
Low:7.26
Close:7.67
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.78
T/O Rate:2.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:3.07
PE(LYR):-5.13

Loading ...

Ocular Therapeutix to Present at Chardan Annual Healthcare Conference

Reuters
·
Yesterday

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

GlobeNewswire
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Ocular Therapeutix (OCUL) and Regeneron (REGN)

TIPRANKS
·
Sep 29

Ocular Therapeutix Price Target Maintained with a $18.00/Share by Needham

Dow Jones
·
Sep 29

Ocular Therapeutix Tumbles on Rival Kodiak's Trial Win, Analyst Calls Selloff Overdone

Reuters
·
Sep 29

Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained

TIPRANKS
·
Sep 29

Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results

TIPRANKS
·
Sep 28

Ocular Therapeutix falls -18.1%

TIPRANKS
·
Sep 28

Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation

TIPRANKS
·
Sep 26

Ocular Therapeutix Grants Inducement Equity Awards for 86,200 Shares, Options Priced at $10.72

Reuters
·
Sep 18

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 18

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 18

Ocular Therapeutix Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 16

Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25

TIPRANKS
·
Sep 16

Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4

MT Newswires Live
·
Sep 15

Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli

TIPRANKS
·
Sep 15

Ocular Therapeutix™ Announces Positive Pre-Nda Meeting with U.S. FDA for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Sep 15

Ocular - Accelerates Commercial Readiness for Potential 2027 Axpaxli Launch

THOMSON REUTERS
·
Sep 15

Ocular - to Submit Axpaxli Nda in Q4 2026

THOMSON REUTERS
·
Sep 15

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

GlobeNewswire
·
Sep 15